[Atrial fibrillation--thromboembolism and prevention]
Related Experiment Video
Updated: Aug 12, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
P Petersen1, G Boysen, J Godtfredsen
1Rigshospitalet, København, neuromedicinsk afdeling.
Insights
Atrial fibrillation increases stroke risk, especially in those with prior heart attacks. Warfarin effectively reduces thromboembolic events, while aspirin
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Context:
- Chronic non-rheumatic atrial fibrillation (AF) carries a significant annual risk of thromboembolic complications (approx. 5%).
- Previous myocardial infarction is a key risk factor for thromboembolism in AF patients.
- Silent cerebral infarction is more prevalent in chronic AF patients compared to those in sinus rhythm.
Purpose:
- To evaluate the efficacy of anticoagulation therapies, specifically warfarin and aspirin, in preventing thromboembolic complications in patients with atrial fibrillation.
- To assess the influence of patient demographics, such as age and history of myocardial infarction, on treatment outcomes.
Summary:
- Warfarin demonstrated effectiveness in reducing thromboembolic complications across three prospective trials.
- Aspirin (325 mg daily) showed efficacy only in patients under 75 years old; its effect was not observed in older patients or in other trials.
- Paroxysmal and isolated AF in younger individuals may present a lower embolic risk.
Impact:
- Provides evidence-based guidance on anticoagulation strategies for atrial fibrillation management.
- Highlights the importance of risk stratification, considering factors like age and prior myocardial infarction, when selecting therapy.
- Informs clinical decision-making regarding stroke prevention in diverse atrial fibrillation patient populations.
Abstract:
Chronic non-rheumatic atrial fibrillation is associated with a risk of thromboembolic complications of about 5% per year. Previous myocardial infarction seems to be a significant risk factor for development of thromboembolic complications in chronic atrial fibrillation, whereas paroxysmal atrial fibrillation and isolated atrial fibrillation in younger patients may be associated with a lower risk of emboli. Silent cerebral infarction occurs more often in chronic atrial fibrillation than among controls in sinus rhythm. Three prospective trials of patients with atrial fibrillation found effect of warfarin on the occurrence of thromboembolic complications. In one study aspirin 325 mg daily was effective in patients below 75 years of age, but not in patients above this age. The other trials revealed no effect of aspirin.
Related Concept Videos
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism III: Nursing Management
Pulmonary Embolism I: Introduction

